<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316743</url>
  </required_header>
  <id_info>
    <org_study_id>Thyroid-001</org_study_id>
    <nct_id>NCT02316743</nct_id>
  </id_info>
  <brief_title>Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism</brief_title>
  <official_title>Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether levothyroxine supplementation is beneficial
      in patients with systolic heart failure and subclinical hypothyroidism on the functional
      class evaluated with a 6 minute walk test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty patients with systolic heart failure and subclinical hypothyroidism will be include in
      a open label trial. They will receive levothyroxine supplementation to determine if their
      functional class will be affect.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance at the 6 minutes walk test</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of the brain natriuretic peptide measurement</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of activin a measurement</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of myostatin measurement</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in heart rate measurement</measure>
    <time_frame>6 months</time_frame>
    <description>Absence / Presence of tachycardia (heart rate &gt; 100 beat per minute) at baseline and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of systolic and diastolic function on transthoracic echocardiogram</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arhythmic (ventricular arrhythmias and supraventricular arrythmias) and ischemic events (myocardial infarction, unstable angina and hospitalization for revascularization)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalisation of thyroid workup</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Systolic Heart Failure</condition>
  <condition>Sub-clinical Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Levothyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levothyroxine supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine supplementation</intervention_name>
    <description>T4 supplementation for heart failure patients with subclinical hypothyroidism.</description>
    <arm_group_label>Levothyroxine</arm_group_label>
    <other_name>T4 supplementation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biochemical diagnosis of subclinical hypothyroidism (TSH between 3.5 and 10 with a
             normal T4)

          -  Systolic heart failure with New-York Heart Association (NYHA) class II or III

          -  Left ventricular ejection fraction under 40%

          -  Stable heart failure for the past 3 months (no IV furosemide or hospital admission)

          -  Beta-blockers and ACE inhibitors titrated to the maximum tolerated dose

        Exclusion Criteria:

          -  Isolated diastolic heart failure

          -  Awaiting cardiac resynchronisation therapy

          -  Impossibility to perform the 6 minutes walk test

          -  Active cancer / Life expectancy under 18 months

          -  Treatment with amiodarone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Nguyen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Nguyen, MD</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>70323</phone_ext>
    <email>michel.nguyen@usherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne L. Couture, MD</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>74326</phone_ext>
      <email>etienne.couture@usherbroke.ca</email>
    </contact>
    <investigator>
      <last_name>Etienne L. Couture, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Farand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre Carpentier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denise St-Cyr Tribble, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Lepage, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mannix Auger-Messier, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <last_update_submitted>December 13, 2014</last_update_submitted>
  <last_update_submitted_qc>December 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Paul Farand</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

